Pediatric Exclusivity for FDA-Approved Drugs by Year
The U.S. Food and Drug Administration (FDA) grants pediatric exclusivity for certain drugs, extending market exclusivity in exchange for studies on pediatric use. This can delay generic competition.
Drugs Granted Pediatric Exclusivity in 2020
In 2020, several drugs received pediatric exclusivity. These included treatments for various conditions, though specific drug names were not detailed in the provided information.
Drugs Granted Pediatric Exclusivity in 2021
The year 2021 saw additional drugs awarded pediatric exclusivity. This expansion aimed to incentivize research into the use of medications in younger populations for a range of diseases.
Drugs Granted Pediatric Exclusivity in 2022
Pediatric exclusivity was granted to multiple drugs in 2022, reflecting an ongoing commitment to understanding and improving pediatric treatment options.
Drugs Granted Pediatric Exclusivity in 2023
In 2023, the FDA continued to grant pediatric exclusivity for new and existing drugs. This practice encourages pharmaceutical companies to conduct necessary studies for pediatric efficacy and safety.
Drugs Granted Pediatric Exclusivity in 2024
As of the latest available information, drugs are continuing to be granted pediatric exclusivity in 2024. This ensures that research into pediatric drug use remains a priority.
How Long Does Pediatric Exclusivity Last?
Pediatric exclusivity typically grants an additional six months of market exclusivity to a drug that already has other forms of exclusivity (like patent or other regulatory exclusivities). This period is added to the end of any existing exclusivity periods.
What is the Purpose of Pediatric Exclusivity?
The primary purpose of pediatric exclusivity is to encourage pharmaceutical companies to conduct clinical trials in the pediatric population. Prior to the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA), there was little incentive for companies to test drugs on children, leading to limited approved uses and dosages for pediatric patients. Pediatric exclusivity addresses this by offering a market reward for undertaking these studies.
Can Generic Drugs Enter the Market Before Pediatric Exclusivity Expires?
Generally, generic drug manufacturers cannot enter the market until all forms of exclusivity, including pediatric exclusivity, have expired. If a drug is granted pediatric exclusivity, the six-month extension will prevent generic competition until it concludes.
Where Can I Find a List of Drugs with Pediatric Exclusivity?
Detailed lists of drugs that have been granted pediatric exclusivity, including the specific years and extensions, can be found through resources like DrugPatentWatch.com [1]. These databases track patent and exclusivity information for pharmaceuticals.
*
**Sources:
[1] https://www.drugpatentwatch.com/